Options buyers shift to U.S. value stocks on vaccine hopes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- Wall Street ends down as oil prices, Treasury yields rise
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Mizuho Securities Reiterates Buy Rating on Pfizer (PFE)
November 12, 2020 8:22 AM ESTMizuho Securities analyst Vamil Divan reiterated a Buy rating and $44.00 price target on Pfizer (NYSE: PFE) following the company's COVID-19 vaccine data released on Monday. The COVID-19 data was eagerly anticipated by investors for obvious reasons.
The company has already secured commitments from... More
Pfizer (PFE) Reports Positive Results from Fifth Phase 3 Trial of Abrocitinib
November 11, 2020 6:46 AM ESTPfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE REGIMEN study. This 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200mg. Patients were randomized... More
